SF
LGND icon

Synovus Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Synovus Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-37
Closed -$3K – 1117
2020
Q2 		$3K Sell
37
-155
-81% -$9.83K ﹤0.01% 1398
2020
Q1 		$9K Buy
192
+155
+419% +$8.79K ﹤0.01% 1600
2019
Q4 		$2K Hold
37
– – ﹤0.01% 1427
2019
Q3 		$2K Hold
37
– – ﹤0.01% 1390
2019
Q2 		$3K Hold
37
– – ﹤0.01% 1290
2019
Q1 		$3K Hold
37
– – ﹤0.01% 1303
2018
Q4 		$3K Hold
37
– – ﹤0.01% 1271
2018
Q3 		$6K Buy
+37
New +$5.58K ﹤0.01% 1205

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Synovus Financial's LGND Position: Q3 2020 in Review

Synovus Financial sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 37 shares — an estimated $3K sold.

Synovus Financial first reported a position in LGND in Q3 2018 and held it in 8 quarters. The position peaked at $9K in Q1 2020. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

  • Synovus Financial reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Synovus Financial sold 37 Ligand Pharmaceuticals shares in Q3 2020, an estimated $3K.
  • Synovus Financial first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 8 quarters.
  • Synovus Financial's Ligand Pharmaceuticals position peaked at $9K in Q1 2020.
  • 252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.